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Summary: In this study, various analytical aspects of the determination of serum prostate-specific antigen are
described as applied to the Abbott IMx PSA and the Hybritech Tandem-Ε PSA assays.
We used mainly specimens from a prostate cancer screening study in progress. A very good comparability between
the assays proved to exist in our hands. The long-run variation (16 months) was also rated as acceptable, both
for the IMx and the Tandem-Ε method. The method of choice, Tandem-Ε, showed good reagent stability over
this period.
We found, however, a difference in accuracy (Tandem-Ε ± 8% higher values) that could not be explained by
comparison with Tandem-R.
Introduction
In the second half of 1994 the Rotterdam section of the
European Randomized Study of Screening for Prostate
Cancer started (1). The goal is to evaluate the feasibility
of a randomized screening study of prostate cancer lo-
cally and eventually, at the European level.
The criteria for biopsy of the prostate in the screening
group are:
1. prostate-specific antigen concentration ^ 4.0 μg/l
2. suspicious digital rectal examination
3. suspicious transrectal ultrasonography
In the definitive protocol the Hybritech Tandem®-E as-
say was chosen for the measurement of total prostate-
specific antigen.
We have been using the Abbott IMx PSA assay for clin-
ical purposes since early 1993. Both assays have been
well-known in the field of clinical chemistry for a
number of years. Nevertheless, we felt the need to assess
some practical issues in our laboratory in relation to the
screening protocol.
In this report we elaborate the comparability of both as-
says statistically as well as the stability of the Hybri-
tech procedure.
Materials and Methods
Samples
All serum samples used were eentrifuged within 2—3 hours after
collection.
Most of the samples coming from participants of the screening
study were analyzed either the same or the following day. In case
of analysis on the following day they were stored at + 4 °C. The
remaining screening samples came from the - 80 °C freezer. In
the Results section the relevant information is presented.
The patient samples used were from our serum bank with well-
characterized serum samples.
The quality control samples we used were either commercial sam-
ples (Bio Rad Lyphochek® Normal and Abnormal) or human serum
pools. Regarding the serum pools, these were, after pooling divided
in 0.3 ml aliquots and stored at — 80 °C.
Methods
The following methods were used exactly according to the instruc-
tions of the manufacturers:
1. Tandem®-E PSA, Hybritech Inc., (USA), a solid-phase two-
site immunoenzymetric assay. Samples containing prostate-spe-
cific antigen are reacted with a plastic bead coated monoclonal
antibody directed toward the prostate-specific antigen molecule,
and with an enzyme-labelled monoclonal antibody directed
against a distinctly different antigenic site on the same prostate-
specific antigen molecule. After washing and incubation with
enzyme substrate the amount of substrate turnover is measured
colorimetrically.
2. Tandem^R PSA, Hybritech Inc., (USA). The same measuring
principle except for the last step, where the radioactivity is mea-
sured (125I γ-radiation).
3. IMx®-PSA, Abbott Laboratories, (USA). Monoclonal antibody-
coated microparticles capture the prostate-specific antigen analyte
and are then reacted with a polyclonal goat antibody-alkaline im-
munoconjugate directed against prostate-specific antigen. After
conversion of the substrate the fluorescent product, 4-methylum-
belliferone, is measured.
In all cases single measurements were performed.
Statistical analysis
All statistical evaluations were done either by the regression
method of Passing & Bablok (2) or by the differential procedure
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as described by Bland & Altman (3, 4) or both. The latter is, for
short, a test on the equality of analytical methods by assessment
of bias and error. Here, we only applied the linear transformation
of the results obtained with the methods under study.
Results
We started the study by comparing 122 specimens from
patients with known prostate cancer at various stages.
We only chose one detection criterium i. e. a reasonable
division of the results over the whole measuring range
0-50 ng/1.
In figure 1 a graph is given of this comparison.
The comparison with cancer patients was followed by a
comparison with fresh samples from the screening pop-
ulation. For practical reasons we had to perform analyses
with the IMx on the day of the participants visit while
the Tandem-Ε analysis was done on the next day.
Figure 2 shows the results after the transformation ac-
cording to the method of Bland & Altman.
Later, we repeated this experiment with a smaller sam-
ple collective and with different IMx and Tandem-Ε rea-
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Fig. 1 Comparison of IMx assay with Tandem-Ε using 122 sam-
ples from patients with prostate cancer.
0.5
Ι
-1
-1.5
2 3
Average (x+y)/2
Fig. 2 Difference plot of 262 observations randomly sampled
from a prostate cancer screening population.
IMx(x): day 1, Tandem-E(y): day 2.
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Fig. 3a Difference plot of 42 observations randomly sampled
from a prostate cancer screening population.
IMx(x): day 1, Tandem-E(y): day 2.
Dashed lines: mean difference (—) and 95% confidence interval
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Fig. 3b The same samples as plotted in figure 3a.
IMx(x): day 1, Tandem-E(y): day 1.
Dashed lines: mean difference (—) and 95% confidence interval
gent lots. We also included a simultaneous comparison
of the IMx and Tandem-Ε assay on the day of visit as
well as on the following day. In figure 3 a + b the sepa-
rate IMx and Tandem-Ε results are compared again with
application of the Bland & Altman procedure.
Because of the differences found in all IMx and Tan-
dem-E comparisons, we decided, not having standard
prostate-specific antigen preparations, to compare
the Tandem-Ε procedure with the Tandem-R assay.
This was done on two separate occasions with dif-
ferent reagent lots, both for the Tandem-Ε and the
Tandem-R assay. In this experiment we used freezer-
stored samples, aliquotted for both assays and ana-
lyzed simultaneously. Both comparisons showed the
same picture. Therefore, we combined the results in
figure 4.
The regression lines of all previous experiments were
calculated. In table 1 the relevant statistical information
is given.
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Fig. 4 Difference plot of 87 observations from freezer stored
screening samples.
Tandem-R = x, Tandem-Ε = y.
Dashed lines: mean difference ( — ) and 95% confidence interval
In addition, in table 2 all remaining information related
to the examination of the differences of all paired meth-
ods, is given.
Finally we checked the imprecision of both assays dur-
ing a long period. The day-to-day coefficients of varia-
tion are given in table 3. In figure 5 we made a subdivi-
sion of the various Tandem-Ε reagent lots we used in
this 16-month period.
Discussion
From all statistical information given it is clear that we
found excellent correlations between the various assays
both for the patient and the screening samples.
However, we cannot deny that we detected an accuracy
problem. Based on the average values of all specimen
collectives and the data from the regression analysis we
saw differences between the IMx and Tandem-Ε assays
of, roughly speaking, 8%, the Tandem-Ε results being
higher.
The difference plots, figures 2 and 3, show explicit evi-
dence of systematic bias between both assays because
in all comparisons the zero values are not included in
the respective confidence intervals of the mean differ-
ences (tab. 2).
On the other hand, looking at the lines of agreement, we
feel that the agreement is acceptable, judging clinically.
There are very few outliers. Of course, there is a differ-
ence between the clinical and the screening samples in
relation to medical decision making. Regarding this as-
Tab. 1 Statistical information on all method comparisons
Comparison Prostate-specific Regression equation
antigen, range
r n
fog/I)
1.
2.
3.
4.
5.
6.
7.
IMx (= x),
IMx (= x),
IMx (= x),
IMx (= x),
IMx, IMx
Tandem-E,
Tandem-E
Tandem-E
Tandem-E
Tandem-E
Tandem-E
(=
(=
(=
(=
y)
y)
y)
y)
Tandem-R (= x), Tandem-Ε (= y)
0-50
0-5
0-5
0-5
0-5
0-5
0-5
.0
.0
.0
.0
.0
.0
y =
y =
y =
y =
y =
y =
y =
1.09x
1.05x
l .llx
l . I l x
0.99x
0.99x
1.17x
-0.06
+ 0.07
-0.06
-0.03
-0.02
-0.03
-0.04
0.986
0.983
0.987
0.988
0.995
0.997
0.997
122
262
42
42
42
42
87
Remarks
1. Comparison 1 = patient samples, comparison 2—7
ing samples.
2. Comparisons 2, 3, 5 and 6: x-axis = day 1, y-axis = day 2,
screen- comparison 4 done on the same day with fresh samples and the
same for 7 with stored sera.
Tab. 2 Statistical differences between all paired methods
Comparison Prostate-specific antigen
Average Mean difference (x-y)
[95% confidence interval](ng/l)
1. IMx (= x), Tandem-E (= y)
2. IMx (= x), Tandem-E (= y)
3. IMx (= x), Tandem-E (= y)
4. IMx (= x), TandenvE (= y)
5. IMx, IMx
6. Tandem-Ε, Tandem-E
7. Tandem-R (= x), Tandem-R (= y)
20.6
1.31
1.48
1.48
1.48
1.60
1.96
22.3
1.43
1.56
1.60
1.42
1.56
2.26
-1.69 [(-2.06)-(-1.32)]
-0.13 [(-0.15)-(-0.11)]
-0.08 [(-0.04)-(-0.12)]
-0.12 [(-0.06)-(-0.18)]
0.06 [0.02-0.10]
0.03 [0.01 - 0.05]
-0.30 [(-0.35) - (-0.25)]
Remarks
I. The same sequence of comparisons was used as described in table 1. 2. Average = mean of all results.
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Tab. 3 Overall day-to-day imprecision I MX and Tandem-E
Control sample
a. IMx
Lyphochck Normal
Lyphochek Abnormal
b. Tandem-E
Pool 1
Pool 2
Pool 3
Prostate-
specific
antigen,
average
(Mg/D
1.8
5.5
4.9
1.7
2.4
CV
(%)
5.6
3.5
3.6
10.3
4.1
n
302
302
302
125
169
Remarks
1. IMx reagent batches: 8.
2. Tandem-Ε reagent batches: see figure 5.
pect it is clear that the well accepted value of the upper
limit of the prostate-specific antigen reference range,
4 μg/l, is at least questionable in relation to different
methods.
Comparing the results shown in figure 3 with those in
figure 2 the same picture arises. In addition, one may
also conclude that the moment of measurement is not
critical (figs. 3a + b). However, the statistical data men-
tioned in table 2 do point to a very small difference
between measuring on the first or the second day. We
will study this phenomenon later on in more detail.
In the comparison study with the screening samples, we
did not split up the samples into the two categories be-
nign prostate hyperplasia and prostate cancer because a
great deal of the samples came from participants who
were not studied any further. However, we assumed that
most of them had benign prostate hyperplasia based on
their age.
This aspect may be of value because it is known that the
IMx assay is more sensitive for free prostate-specific
antigen than Tandem-Ε which measures equimolarly (5).
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Fig. 5 Day-to-day variation of Tandem-Ε assay measured with 3
different human serum pools and 9 different reagent batches.
All measurements per batch were between 20 and 40 days. Average
values and 95% confidence intervals are plotted.
Our results are comparable to those published by Brawer
et al. (6), Dnistrian et al. (16) and Wright et al. (7)
though the study populations and practical conditions
differ. Brawer et al. show small differences in assay be-
haviour by plotting IMx and Tandem-Ε results with be-
nign prostate hyperplasia and prostate cancer patient
samples in the prostate-specific antigen range of 2.0-
10.0 μ§/1. The number of specimens in both cases how-
ever, is limited.
We struggled with the results shown in figure 4, regard-
ing the difference in accuracy between the Tandem-E
and the Tandem-R assays. It was not our intention to
check this methodological aspect. On the contrary, it
proved to be a logical consequence of the studies de-
scribed earlier (figs. 1-3), because very often the Tan-
dem-R assay has the status of reference technique in the
medical literature.
According to the information of the manufacturer both
assays should show equality with application of the
same antibodies. We accept that information, however,
the detecting systems differ considerably. The situation
may be comparable to what Zucchelli et al. showed in
their comparison studies with 8 CA 19-9 assays, all with
different labels (8). They found a large variation in re-
sults despite the use of the same (Centocor) antibodies.
Our findings concerning the range studied, i. e. up till
5.0 μ§/1, were confirmed by Hall et al. (9) and by most
of the quality assessment surveys held in The Nether-
lands and Germany.
At the moment we have no explanation for the various
accuracy differences we found. The Tandem-Ε assay is
a partly automated method that we ran exactly according
to the manufacturer's instructions. The IMx is fully auto-
mated. The Tandem-R assay is the only manual assay
and performed by us with calibrated glassware. The
availability of internationally accepted prostate-specific
antigen standards should help us solve this dilemma
(10,11).
The last item we want to describe concerns the im-
precision of the prostate-specific antigen assays we
compared. Recent literature discusses the variability of
especially the IMx method (12, 13). Here, we do not
want to go into detail in analyzing the performance of
this method because it is clear that the overall coeffi-
cients of variation are acceptable as can be seen in table
3 and moreover, in line with what is published elsewhere
(14, 15).
We prefer to focus on the Tandem-Ε assay. Table 3 also
shows acceptable coefficients of variation for the Tan-
dem-E method. The same holds for the various batches
of reagents we used during a 16-month period, as can
be seen in figure 5. We have no explanation for the small
dip in the results obtained with pool 2.
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In conclusion we may state that the Tandem- PSA as-
say proved to be a fairly robust method in our hands,
well applicable to our desired goal.
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